Table 1.

AD modifying peptides with brief description. Abbreviations: act. (activity); agg. (aggregation); att. (attenuates); hyperph. (hyperphosphorylation); infl. (inflammation); NFF (neurofilament formation); pII. c.t. (phase II clinical trials); pl. form. (plaque formation); ref. (reference); stim. (stimulates); α-S (α-secretase); ● (observed effect).

Peptide Name and Ref.	Att. Brain Infl.	Att. Aβp Agg./Pl. Form.	Att. Tau Hyperph./NFF	Stim. Neurog.	Improves Cognition	Stim. α-S Act.
Ac-Leu-Pro-Phe-Phe-Asp-NH2 (iAb5p), [249]		●
LPfFFD-PEG, [253,254]		●
D-(PGKLVYA), [255]		●
RI-OR2-TAT, [260]	●	●		●
cyclo(17, 21)-(Lys17, Asp21)Aβ(1-28), [366]		●
SEN304, SEN1576, [265,266]		●
α sheet peptides, [267]		●
NAP, [268,273,361]		●	●		● (pII. c.t.)
D4-F, [274]		●			●
D3, [356]		●			●
PP-Leu, [275]		●
TFP5, [355]	●	●	●
wtNBD, [358]	●	●			●
PACAP38, [360]					●	●
insulin, [181,183,189,191,362,363,364,365]					● (pII. c.t.)